[ Price : $8.95]
FDA extends by three months its review of a Bristol Myers Squibb BLA for lisocabtagene maraleucel for treating adults with relapse...[ Price : $8.95]
FDA approves a Novartis Pharmaceuticals NDA for Tabrecta (capmatinib) for treating certain adult patients with non-small cell lung...[ Price : $8.95]
FDA clears a HeadsafeIP 510(k) for its Nurochek system for brain assessment in patients aged 14 years and older.[ Price : $8.95]
Two drug industry associations praise FDA for improving the Purple Book and suggest further enhancements.[ Price : $8.95]
An in-depth McClatchy News article explores the fears of some public health officials that FDAs haste to authorize some tests and ...[ Price : $8.95]
TherapeuticsMD asks FDA to issue product-specific guidance putting restrictions on applications for a generic form of Imvexxy.[ Price : $8.95]
Former FDAer Thomas Laughren says improved patient selection for schizophrenia drug clinical trials could reduce the problem of in...[ Price : $8.95]
FDA issues an immediately-in-effect guidance relating to the new requirement for medical device manufacturers to notify FDA about ...